Effects of Polyquaternium- and Benzalkonium-Chloride-Preserved Travoprost on Ocular Surfaces: An Impression Cytology Study
Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - June 5, 2014 Category: Opthalmology Tags: article Source Type: research
Improving adherence to glaucoma medication: a randomised controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study)
Background:
Improving adherence to ocular hypertension (OH)/glaucoma therapy is highly likely to prevent or reduce progression of optic nerve damage. The present study used a behaviour change counselling intervention to determine whether education and support was beneficial and cost-effective in improving adherence with glaucoma therapy.
Methods:
A randomised controlled trial with a 13-month recruitment and 8-month follow-up period was conducted. Patients with glaucoma/OH attending a glaucoma clinic and starting treatment with travoprost were approached. Participants were randomised into two groups and adherence was measur...
Source: BMC Ophthalmology - Latest articles - March 24, 2014 Category: Opthalmology Authors: Heidi CateDebi BhattacharyaAllan ClarkRichard FordhamRichard HollandDavid Broadway Source Type: research
Confocal Microscopy of Epithelial and Langerhans Cells of the Cornea in Patients Using Travoprost Drops Containing Two Different Preservatives.
Abstract
The recently developed confocal cornea microscopy offers the opportunity to examine pathologies of the cornea and to gain insight into the activity of innate immunity. We aimed to investigate the corneal epithelial and Langerhans cell (LC) densities along with dry eye parameters in primary open-angle glaucoma (POAG) subjects, treated with either of two commercially available travoprost 0.004 % topical medications containing different preservatives. (1: benzalkonium chloride 0.015 % (TravBAK) and 2: polyquaternium-1 (PQ) 0.001 % (TravPQ). Consecutive case series of nineteen POAG patients on Trav...
Source: Pathology Oncology Research - March 13, 2014 Category: Pathology Authors: Marsovszky L, Resch MD, Visontai Z, Németh J Tags: Pathol Oncol Res Source Type: research
Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety.
CONCLUSION: Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic patterns.
PMID: 24615289 [PubMed - as supplied by publisher] (Source: Advances in Therapy)
Source: Advances in Therapy - March 11, 2014 Category: Drugs & Pharmacology Authors: Kuwayama Y, Nomura A Tags: Adv Ther Source Type: research
Activation of the Prostanoid FP Receptor Inhibits Adipogenesis Leading to Deepening of the Upper Eyelid Sulcus in Prostaglandin-Associated Periorbitopathy [Glaucoma]
Conclusions.
Prostaglandin analogues have the potential to inhibit adipogenesis through FP receptor stimulation. Although these findings should be further analyzed in model systems more closely related to orbital fat, PG analogues may directly lead to reduced orbital fat by inhibiting adipogenesis. (Source: Investigative Ophthalmology)
Source: Investigative Ophthalmology - March 4, 2014 Category: Opthalmology Authors: Taketani, Y., Yamagishi, R., Fujishiro, T., Igarashi, M., Sakata, R., Aihara, M. Tags: Glaucoma Source Type: research
Bilateral Acute Angle-Closure Glaucoma Following Treatment with Topiramate for Headache
Conclusion
TPM-induced AACG is a rare serious adverse event leading to blindness but is preventable, when diagnosed early and by instituting appropriate treatment. (Source: Neurology and Therapy)
Source: Neurology and Therapy - December 1, 2013 Category: Neurology Source Type: research
The Diurnal and Nocturnal Effect of Travoprost With SofZia on Intraocular Pressure and Ocular Perfusion Pressure
Conclusion: Travoprost with sofZia significantly lowers IOP throughout the diurnal and nocturnal periods, and increases ocular perfusion pressure in the diurnal, but not the nocturnal, period in open-angle glaucoma and ocular hypertension. The treatment effect on IOP endures for at least 84 hours after the last dose. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - October 31, 2013 Category: Opthalmology Authors: Leonard K. Seibold, Malik Y. Kahook Tags: Original Articles Source Type: research
A Randomized, Prospective Study of Bimatoprost 0.01% or Travoprost/Timolol in Patients Previously Treated with Latanoprost and Timolol to Reduce Intraocular Pressure
Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - September 28, 2013 Category: Opthalmology Tags: article Source Type: research
Hypotensive Effect of Latanoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in NTG Patients: A Randomized, Multicenter, Crossover Clinical Trial [Clinical Trials]
Conclusions.
The additional reduction in IOP was greater with TTFC than with LTFC, and their tolerability profiles were similar. (http://www.umin.ac.jp/ctr/ number, UMIN 000005974.) (Source: Investigative Ophthalmology)
Source: Investigative Ophthalmology - September 17, 2013 Category: Opthalmology Authors: Shoji, T., Sato, H., Mizukawa, A., Hirota, N., Enoki, T., Kojima, T., Kanda, T., Takeuchi, M. Tags: Clinical Trials Source Type: research
Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits
Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - August 28, 2013 Category: Opthalmology Tags: article Source Type: research
Influence of BAK-Preserved Prostaglandin Analog Treatment on the Ocular Surface Health in Patients with Newly Diagnosed Primary Open-Angle Glaucoma.
Conclusions. This study showed that BAK-preserved travoprost 0.004% is an effective medication in newly diagnosed POAG patients, but its long-term use may negatively influence ocular surface health by disrupting the tear film stability. Further studies are needed to better understand the clinical effects of different preservative types and concentrations on the ocular surface.
PMID: 23971041 [PubMed - in process] (Source: Biomed Res)
Source: Biomed Res - August 25, 2013 Category: Research Authors: Tomić M, Kaštelan S, Metež Soldo K, Salopek-Rabatić J Tags: Biomed Res Int Source Type: research
Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost
ConclusionsPAP is as common as other adverse effects when careful examinations are performed and is more frequent and more severe in bimatoprost users. The loss of the periorbital fat pad is the first sign to occur during the evolution of PAP, especially in older patients. (Source: Clinical and Experimental Ophthalmology)
Source: Clinical and Experimental Ophthalmology - July 12, 2013 Category: Opthalmology Authors: Murat Kucukevcilioglu, Atilla Bayer, Yusuf Uysal, Halil I Altinsoy Tags: Clinical Science Source Type: research
Efficacy of timolol 0.1% gel and a prostaglandin
analog in an unfixed combination compared to the corresponding fixed combinations.
Conclusion: In this pilot study, PGA and timolol seems to be more effective in POAG treatment when administered as unfixed combinations, reducing both IOP and daily fluctuations. The once a day timolol 0.1% gel-forming carbomer may be a valuable option in PGA-timolol unfixed combination regimen.
PMID: 23640513 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - April 15, 2013 Category: Opthalmology Authors: Nucci C, Varesi C, Martucci A, Cesareo M, Cedrone C, Mancino R, Cerulli L Tags: Eur J Ophthalmol Source Type: research
Comparison of 24-hour Intraocular Pressure Reduction Obtained with Brinzolamide/Timolol or Brimonidine/Timolol Fixed-Combination Adjunctive to Travoprost Therapy
Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - April 3, 2013 Category: Opthalmology Tags: article Source Type: research
Comparative Cross-sectional Analysis of the Effects of Topical Antiglaucoma Drugs on the Ocular Surface.
CONCLUSION: Long-term treatment with BAK-containing antiglaucoma medication appears to be the main contributor to corneal toxicity and to do so in a dose-dependent manner. Formulations containing beta-blockers also appear to contribute to corneal toxicity.
PMID: 23564224 [PubMed - in process] (Source: Advances in Therapy)
Source: Advances in Therapy - April 1, 2013 Category: Drugs & Pharmacology Authors: Lee S, Kim MK, Choi HJ, Wee WR, Kim DM Tags: Adv Ther Source Type: research
